Two Deaths Linked to the Chikungunya Vaccine Highlight Risks of Unrepresentative Clinical Trials

Two deaths linked to the chikungunya vaccine highlight risks of unrepresentative clinical trials

The European Medicines Agency (EMA) has recommended restricting the use of the first vaccine developed against chikungunya — an infectious disease transmitted by mosquitoes in tropical areas that causes, among other symptoms, severe joint pain that lasts for several months or even years — in people aged over 65. The measure comes after at least 17 serious adverse events, two of them fatal, were reported in people over 62 years of age who had rec…

CDC Approves Recommendations for Chikungunya Vaccines

The Centers for Disease Control and Prevention has accepted an advisory panel’s recommendations on vaccines for chikungunya disease, which is transmitted to humans by mosquitoes. The recommendations were made by the health agency’s Advisory Committee on Immunization Practices (ACIP) during a meeting in April, according to the CDC. ACIP recommended the virus-like particle chikungunya vaccine for people aged 12 or over who are traveling to a count…